Search results
Showing 46 to 60 of 112 results for bladder cancer
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Awaiting development Reference number: GID-TA11517 Expected publication date: TBC
This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.
Laparoscopic prostatectomy for benign prostatic obstruction (HTG176)
Evidence-based recommendations on laparoscopic prostatectomy for benign prostatic obstruction. This involves removing the prostate through small cuts in the abdomen, using a fine telescope to see inside the body (keyhole surgery).
View recommendations for HTG176Show all sections
Sections for HTG176
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued Reference number: GID-TA10394
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (HTG667)
Evidence-based recommendations on focal therapy using high-intensity focused ultrasound for localised prostate cancer. This involves using high-intensity focused ultrasound to heat up and destroy only the areas of the prostate with cancer (focal therapy). The aim is to destroy the cancer while reducing damage to healthy prostate tissue.
View recommendations for HTG667Show all sections
Awaiting development Reference number: GID-TA10967 Expected publication date: TBC
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
Minimally invasive radical hysterectomy for early stage cervical cancer (HTG565)
Evidence-based recommendations on minimally invasive radical hysterectomy for early stage cervical cancer. This involves removing the uterus, cervix, upper vagina and some lymph nodes.
View recommendations for HTG565Show all sections
In development Reference number: GID-TA11767 Expected publication date: 04 November 2026
High-intensity focused ultrasound for prostate cancer (HTG70)
Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.
View recommendations for HTG70Show all sections
Sections for HTG70
Cryotherapy as a primary treatment for prostate cancer (HTG91)
Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.
View recommendations for HTG91Show all sections
Sections for HTG91